ReviewBiomedicines2024
Chronic Kidney Disease Progression-A Challenge.
Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Oral Health in Early and Advanced Stages (1-4) of Chronic Kidney Disease: A Systematic Review and Meta-Analysis.International dental journal · 2026Pooled it
- Effects of exercise training on depression, anxiety, and physical health-related quality of life in end-stage renal disease patients receiving maintenance hemodialysis: a systematic review and meta-analysis of randomized controlled trials.Frontiers in public health · 2026Pooled it
- Pooled it
- Abdominal aortic calcification index and prognosis in patients with chronic kidney disease: a meta-analysis.Frontiers in medicine · 2026Pooled it
- Lower proteinuria is better for patients with IgA nephropathy: a systematic review.Frontiers in nephrology · 2025Pooled it
- Trial
- Dual Antioxidant Supplementation With N-Acetylcysteine and Taurine (NefrosaveCardiology research · 2026Article
- Review
- Acute Kidney Injury-to-Chronic Kidney Disease Transition-Associated Macrophage Subtypes: Biological Functions and Intercellular Crosstalk.International journal of molecular sciences · 2026Review
- Review
- Genetic Associations with Temporal Modeling of Alzheimer's Disease Progression Supports a Novel Paradigm for Disease Risk.medRxiv : the preprint server for health sciences · 2026Article
- Cognitive frailty and adverse outcomes in older people with maintenance hemodialysis: a multicenter prospective cohort study.BMC geriatrics · 2026Article
- Article
- Knowledge, Attitudes, and Practices Survey on Hypertensive Nephropathy Among Hypertensive Patients in Xinjiang, China: A Cross-Sectional Study.Journal of general internal medicine · 2026Article
- Development and Psychometric Validation of a Multidimensional Ecological Model-Based Awareness Scale for Patients with Stage 3-4 Chronic Kidney Disease.Healthcare (Basel, Switzerland) · 2026Article
- Diabetes Duration Is Associated with Declining Kidney Function: eGFR and CKD Burden Across Duration.Journal of clinical medicine · 2026Article
- Efficacy of warm acupuncture combined with conventional therapy in patients with chronic glomerulonephritis.Medicine · 2026Article
- Biomarkers in Disease Diagnosis and Monitoring: Insights into Clinical Applications and Mass Spectrometry-based Detection.Applied biochemistry and biotechnology · 2026Review
- Mutations in ammonia transporter RhBG that impair NHThe Journal of physiology · 2026Article
- They Are Like Family: A Qualitative Thematic Analysis of Nurses' Experiences in a Tshwane Dialysis Unit.Healthcare (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a progressive condition characterized by a continuous decline in renal function, independent of the initial cause of damage or external factors such as infection, inflammation, or toxins. The accurate measurement of renal function, typically assessed using the glomerular filtration rate (GFR), is crucial for managing CKD. The most accepted hypothesis for CKD progression is glomerular damage caused by hyperfiltration. Various factors can accelerate CKD progression, and several biomarkers have been identified to monitor this progression. Numerous studies have explored the risk factors associated with CKD progression, and some of these factors can be modified. Additionally, several drugs are now available that can reduce CKD progression. This review summarizes recent publications and highlights potential future research directions in CKD progression. It discusses the evolution of GFR measurement methods, the mechanisms driving CKD progression, and the latest findings on biomarkers and risk factors. Furthermore, it explores therapeutic strategies, including dietary modifications and pharmacological interventions, to slow CKD progression. Understanding these mechanisms and interventions is crucial for developing effective therapeutic strategies to prevent or slow CKD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.